Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales

Enanta Pharmaceuticals' (NASDAQ: ENTA) got off to a great start in 2019 with its shares soaring more than 40%. It's been downhill since the first quarter, though. The pharma stock is now down more than 10% year to date.